Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Doripenem→

Doripenem PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
148016-81-3
PubChem CID
73303
Molecular formula
C15H24N4O6S2
Molecular weight
420.5 g/mol
Drug class
Carbapenem beta-lactam antibacterialbroad-spectrum parenteral antibiotic
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial cell-wall peptidoglycan synthesis, resulting in bactericidal activity against susceptible Gram-positive, Gram-negative and anaerobic organisms.
Indications / reported uses
  • Treatment of complicated intra-abdominal infections and complicated urinary-tract infections, including pyelonephritis, caused by susceptible bacteria where doripenem is authorised; current availability and restricted use due to mortality signal in ventilator-associated pneumonia must be considered

Sources: US FDA — Doribax prescribing information and safety restrictions · NLM MeSH — Doripenem · FDA product information

Identification source: PubChem record (CID 73303). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Carbapenem beta-lactam antibacterial; broad-spectrum parenteral antibiotic

Mechanism of action

Binds penicillin-binding proteins and inhibits bacterial cell-wall peptidoglycan synthesis, resulting in bactericidal activity against susceptible Gram-positive, Gram-negative and anaerobic organisms.

General use cases

  • Treatment of complicated intra-abdominal infections and complicated urinary-tract infections, including pyelonephritis, caused by susceptible bacteria where doripenem is authorised; current availability and restricted use due to mortality signal in ventilator-associated pneumonia must be considered

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Doripenem PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Doripenem Permitted Daily Exposure (PDE) report (the Doripenem PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Doripenem Occupational Exposure Limit (OEL) report (the Doripenem OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.